Camlipixant
Camlipixant is an investigational new drug that has been evaluated for the treatment of chronic cough and irritable bowel syndrome.
≈ 1 min read
Camlipixant. encyclopegia.org, snapshot enwiki-001367448112. /a/camlipixant
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Camlipixant is an investigational new drug that has been evaluated for the treatment of chronic cough and irritable bowel syndrome. It is a P2X3 receptor antagonist. On July 17th 2026, GSK announced that the drug had failed to meet its primary endpoint in one of two phase 3 trials, and would be discontinuing development for chronic cough. The drug will continue to be investigated for use in irritable bowel syndrome.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367448112 under CC BY-SA 4.0; modifications have been made.